AstraZeneca's Dapagliflozin tablets get DCGI nod; will soon be used to treat patients with chronic kidney disease

AstraZeneca Pharma India on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for Dapagliflozin tablets for the treatment of patients with chronic kidney disease.

The company has "received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets 10 mg," AstraZeneca Pharma India said in a filing to BSE.

Dapagliflozin tablet 10 mg is now approved for additional indication, for the treatment of patients with chronic kidney disease(CKD) up to Stage III, it added.

The receipt of this permission paves way for the launch of the product into a new disease area to nephrologists in India, the filing said.

FPJ Shorts

'Vande Mataram' Row Sparks Outrage: Muslim Activists Condemn MLA Abu Asim Azmi's Stance And Minister Mangal Prabhat Lodha's Retaliation

Bombay HC Permits 15-Year-Old Rape Survivor With Borderline IQ To Terminate 27-Week Pregnancy; Cites Grave Mental Health Risks

Bombay HC Acquits Man After 27 Years In Wife’s Alleged Suicide Case; Cites ‘Mere Unhappiness Not Proof Of Cruelty'

Bombay HC To Hear Amol Palekar’s Petition Challenging Mandatory Pre-Censorship Of Plays On December 5

In July 2020, the company had said that it has received DCGI nod for Dapagliflozin tablets for treatment of patients suffering from heart failure with reduced ejection fraction.

The drug is also sold in the country as a diabetic medicine used for lowering blood sugar in adults with type 2 diabetes.

Read Also

Pfizer withdraws application for emergency use of its COVID-19 vaccine in India